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New Horizons in Multimorbidity in Older Adults 
Abstract 
The concept of multimorbidity has attracted growing interest over recent years, and more latterly 
with the publication of specific guidelines on multimorbidity by the National Institute for Health and 
Care Excellence (NICE).  Increasingly it is recognised that this is of particular relevance to 
practitioners caring for older adults, where multimorbidity may be more complex due to the overlap 
of physical and mental health disorders, frailty and polypharmacy.  The overlap of frailty and 
multimorbidity in particular is likely to be due to the widespread health deficit accumulation, leading 
in some cases to functional impairment.  The National Institute for Health and Care Excellence (NICE) 
guidelines identify ‘target groups’ who may benefit from a tailored approach to care that takes their 
multimorbidity into account, and make a number of research recommendations.  Management 
includes a proactive individualised assessment and care plan, which improves quality of life by 
reducing treatment burden, adverse events, and unplanned or uncoordinated care. 
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Key Points:-  
 Multimorbidity is defined by two or more long-term conditions and increases with age. 
 A considerable overlap can be seen between frailty and multimorbidity. 
 The recent National Institute for Health and Care Excellence (NICE) guidelines on 
multimorbidity highlight target groups who require an individualised assessment and care 
plan. 
 The complexity of multimorbidity in the context of frailty, dementia and polypharmacy bears 
a substantial healthcare burden.   
 
Introduction 
Multimorbidity is defined by the presence of two or more long-term conditions (LTCs), which are 
those that cannot currently be cured but can be controlled through medications or other 
treatments.  Multimorbidity increases with both social deprivation and age, with almost a quarter of 
the UK population affected as a whole and two-thirds of people aged 65 years or over [1].  
Compared to those with one or no LTCs, people with multimorbidity have increased risk of 
functional decline [2, 3], poorer quality of life [4, 5], greater health-care use [6, 7] and increased 
mortality [8, 9]. 
Numerically, most people with multimorbidity are middle-aged, and community-dwelling.  Reflecting 
this, the concept of multimorbidity arose in the context of primary care as a remedy to both a 
recognised narrow focus on single diseases and as means of underscoring the need for generalism in 
the management of people, rather than diseases.  Much of the multimorbidity research to date has 
focused on combinations of chronic, frequently synergistic diseases such as diabetes and cardiac 
disease in primary care.   
Geriatricians are accustomed to managing multiple chronic conditions on a regular basis, yet until 
recently, there has been little to support multimorbidity as an entity in its own right.  The publication 
of guidelines on multimorbidity by the National Institute for Health and Care Excellence (NICE) [10] 
and supporting editorials in both Age and Ageing [11] and the Journal of the American Geriatrics 
Society [12] have highlighted its importance to both clinicians and researchers, and emphasised the 
role of geriatricians and specialist practitioners in its recognition and management.  Additionally, the 
NICE guidelines have contributed to advancing understanding by codifying frailty as a clinical entity 
in the wider context of multimorbidity. 
This review will focus on recent findings in multimorbidity and discuss the interrelationship between 
multimorbidity and frailty, particularly in older people.  Neurodegenerative disease in older people 
will be highlighted as an exemplar of a target group from the NICE guidelines.   
Multimorbidity: applicability to geriatricians 
Multimorbidity is of particular relevance to geriatricians, as the number of morbidities and 
proportion of the population with multimorbidity increases substantially with age [1].  In addition, 
the complexity of multimorbidity in the context of coexisting conditions such as frailty and dementia, 
plus associated polypharmacy that is widespread in older adults, has a considerable burden at an 
individual level, and major implications from a health service, social care and policy perspective 
(Figure 1). 
 
Figure 1: Diagram to indicate the need for an approach to care that takes account of multimorbidity 
[10]. Reproduced with permission National Guideline Centre (2016) Multimorbidity: clinical 
assessment and management (NG56).  Published by the National Guidelines Centre at The Royal 
College of Physicians, 11 St Andrews Place, Regent’s Park, London, NW1 4LE. Copyright © 
NGC. Reproduced by permission. 
 
  
Prior to the NICE guidelines, a key difficulty in prioritising multimorbidity was that, by definition, it 
affects approximately 25% of the UK population, which equates to around 15 million people; this is 
an insurmountably large number to target for intervention [1, 11].  Furthermore, traditional 
multimorbidity measures such as disease counts [13] or comorbidity indices [14] may fail to 
characterise the common characteristics of multimorbidity in old age.  A key strength of the NICE 
guidelines is the identification of target groups with multimorbidity who have especially high levels 
of complexity, so need an approach to care that takes account of multimorbidity (Box 1). The large 
majority of the target groups are closely aligned with the patient populations seen by geriatricians 
on a daily basis, for example, people who are frail in virtue of accumulated deficits that often include 
combinations of functional impairment, falls, coexisting physical and mental health conditions, and 
polypharmacy [10, 11, 15].  
  
 
 
 
 
 
 
As advancing age is associated with increasing multimorbidity, some older people can be particularly 
challenged to maintain health and wellbeing with increasing number and severity of individual 
conditions, and associated frailty [16].  Despite significant levels of disease, however, baseline 
findings from the Newcastle 85+ Study demonstrated that many 85 year olds rated their health as 
good or very good [17], highlighting that different disease-related factors may be of particular 
importance.  Multimorbidity may have a greater impact on overall health and well-being in some 
people if it is in disparate conditions; for example, conditions affecting physical and mental health 
compared to closely related comorbidities (such as ischaemic heart disease, hypertension and 
diabetes); the former encompasses neurodegenerative diseases which disproportionately affect 
older adults [10].   
The majority of older adults have two or more LTCs [1], so use more primary and secondary care 
services [18] and can expect more fragmented care compared to those with only one or two 
recognised illnesses [6].  Care home residents are almost universally affected by multimorbidity, with 
a mean number of chronic conditions found to be 17 in one German study [19].  When compared 
with those with single chronic conditions, older adults with multimorbidity are at much greater risk 
of becoming care dependent, with almost a third requiring care home placement over a five year 
period in contrast to a quarter of the non-multimorbid population [20] .  Finally in terms of relevance 
to geriatricians, multimorbidity increases the risk of experiencing intrusive problems such as pain, 
incontinence, falls, pressure ulcers and delirium.  Specific diseases such as Parkinson’s disease (PD), 
cerebrovascular disease and peripheral artery disease appear to be especially problematic coexisting 
LTCs as they are associated with particularly high levels of these ageing syndromes [21]. 
The overlap of multimorbidity and frailty 
Most older people with frailty have multimorbidity, but the majority of people with multimorbidity 
are not phenotypically frail [22], despite being at greater risk for adverse health outcomes than their 
age peers.  Although separate concepts, it is apparent that there is a large overlap between frailty 
and multimorbidity [23], and this is recognised in the recent NICE guidelines [10].  At younger ages, a 
single disease process characteristically dominates which, over time, can become part of a wider 
multimorbidity complex.  The accumulation of multiple long-term conditions alongside other health 
deficits (clinical signs, symptoms, impairments) can lead to the development of frailty, which 
identifies people at especially high risk of adverse outcomes such as falls, disability, nursing home 
Box 1: NICE ‘target groups’ of people who may benefit from an approach to care that 
takes account of their multimorbidity: 
 they find it difficult to manage their treatments or day-to-day activities 
 they receive care and support from multiple services and need additional 
services 
 they have both long-term physical and mental health conditions 
 they have frailty or falls 
 they frequently seek unplanned or emergency care 
 they are prescribed multiple regular medicines. 
 
admission, hospitalisation and mortality [15, 24] (Figure 2).  Frailty can usefully be considered 
therefore as a method of identifying older people with multimorbidity who are especially vulnerable 
to a wide range adverse outcomes that are important from an individual and societal perspective. 
Importantly, established models of frailty such as the phenotype model and cumulative deficit 
model incorporate aspects of function such as evidence of mobility impairment or activities of daily 
living, which are not ordinarily incorporated into multimorbidity models.  This is especially relevant 
because functional impairments are often targeted as a core component of evidence-based 
interventions to improve outcomes for older people with frailty, such as comprehensive geriatric 
assessment and exercise programmes.  Furthermore, evidence indicates that the association 
between multimorbidity and mortality is lost when adjusted for functional impairment [25].  Taken 
together, this evidence highlights the critical importance of identifying frailty in older people with 
multimorbidity as a key method of targeting those who may benefit from provision of interventions 
to improve outcomes. 
 
Figure 2: Flowchart of the evolution of a single disease process to multimorbidity, functional 
impairment and finally frailty 
 
 
 
The underlying pathophysiology of frailty is characterised by a prominent decrease in physiological 
reserve and failure of homeostatic mechanisms that are more pronounced than would be expected 
from normal ageing [15].  It is proposed that epigenetic mechanisms, in combination with both 
genetic and environmental factors, generate cumulative molecular and cellular damage, triggering a 
cascade of further negative insults [15].  At a cellular level, alterations in the neuroendocrine 
production of insulin-like growth factor-1 (IGF-1) [26], testosterone [27] and cortisol [28] have been 
implicated in frailty, together with abnormalities of the inflammatory response and associated 
changes in inflammatory cytokines [15, 29, 30].  Analogously, a recent discussion paper proposed 
that multimorbidity is the end result of failure of multiple physiological networks interacting with 
psychosocial and behavioural factors of the individual [31].  These networks include genomic, 
proteomic, metabolomic, neuroendocrine, immune and bioenergetics processes.  Particular 
emphasis was placed on the autonomic nervous system, the hypothalamic-pituitary-adrenal axis and 
its subsequent influence on cytokine production, and on mitochondrial function; all of which may 
have important implications for interventions in multimorbidity [31].  This accumulating evidence 
has led to a proposed shift away from defining multimorbidity as a simple disease count to reflect a 
more widespread health deficit accumulation [10, 32]. 
In view of the overlap between frailty and multimorbidity, the NICE guidelines suggest that we 
should consider the identification of frailty as one way to identify those with multimorbidity who 
may benefit from a tailored approach to care [10].  In hospital outpatient settings, the use of self-
reported health status, the ‘Timed Up and Go’ test, gait speed, PRISMA-7 questionnaire or self-
reported physical activity were all recommended tools for identifying frailty.  Although ostensibly 
pragmatic, the difficulty faced with the use of frailty as a targeting characteristic in the NICE 
guidelines is that these physical performance measures of frailty are not advocated in acute settings, 
thereby limiting these instruments for geriatricians working with in-patients. 
The use of frailty to target interventions for people with multimorbidity was also prominent in the 
NICE guideline research recommendations.  For example, frailty was identified as one method of 
identifying a target group for a clinical trial evaluation of a holistic assessment and management 
intervention for people in the community living with high levels of multimorbidity.  Furthermore, 
frailty was identified as a method of targeting for future randomised controlled trial evaluations of 
deprescribing interventions to reduce treatment burden for people with multimorbidity.           
Multimorbidity in long-term conditions: the example of neurodegenerative disease and 
multimorbidity 
The majority of people with one LTC have multiple LTCs, yet most clinical guidelines focus almost 
exclusively on single conditions [33].  If guidelines are followed for each comorbidity in older adults, 
invariably polypharmacy ensues, leading to probable drug-drug interactions and their associated 
consequences, which may be more pronounced in frailer and/or cognitively impaired people [33, 
34].  The preventative effect of each individual drug is likely to be less in those with multiple drug 
use, and is reduced again in those with a limited life expectancy [33].  Additionally, the evidence for 
the individual guidelines often comes from younger, fitter patients, as older adults with 
multimorbidity are often excluded from clinical trials, limiting the generalisability to the typical 
population seen by practitioners working with older people [35, 36]. 
Neurodegenerative diseases provide a useful example of the NICE guideline target group of people 
with multimorbidity living with physical and mental health problems.  Parkinson’s disease (PD) is the 
second commonest neurodegenerative disease in economically developed countries and is an 
example of an age-related multisystem disease encompassing both physical and mental health 
problems such as dementia [37], mild cognitive impairment (MCI) [38], depression [39] and 
psychosis [40].  A recent study on the impact of a large number of differing comorbidities on quality 
of life in people with multimorbidity reported that PD had the most pronounced negative effect [41], 
whilst additional work in Germany on multimorbidity and long-term care dependency highlighted 
that the conditions with the highest risk for care home admission were PD and dementia [20].  
General polypharmacy is common in PD, with UK primary health-care data demonstrating that 
19.2% of PD patients aged 55 and over are on 10 or more medications compared to 6.2% of controls 
[MacLean G et al, under review].  The same study showed that compared to 22.9% of controls, only 
7.4% of PD subjects had no other comorbidities.  Taken together, these studies illustrate that 
multimorbidity in PD also has a significant impact on healthcare expenditure in terms of 
institutionalisation and medication use, with evidence that excess expenditures associated with PD 
are at least partly driven by coexisting LTCs [42].  Moreover, there is evidence that multimorbidity 
may also drive disease progression or complications in PD.  One study found evidence for a small 
negative effect of cardiovascular and diabetes comorbidities on cognition, which was independent of 
age, PD duration and severity, and medication use [43].  In the general (non-PD) population, 
multimorbidity has been associated with greater longitudinal risk of MCI or dementia [44], and can 
accelerate cognitive decline in those with underlying dementia [45]. 
Managing multimorbidity 
Familiar to geriatricians, the NICE guidelines advocate an approach to care that takes account of 
multimorbidity, involving a personalised assessment and the development of an individualised 
management plan [10].  The aim is to improve quality of life by reducing treatment burden, adverse 
events, and unplanned or uncoordinated care. The approach takes account of a person's individual 
needs, preferences for treatments, health priorities and lifestyle. It aims to improve coordination of 
care across services, particularly if this has become fragmented.  This approach should be considered 
if the person requests it or if any of the issues apply as outlined in box 1 [10]. 
The NICE guidelines expand on a previous approach detailed by the American Geriatrics Society 
(AGS) [46].  The guidelines encouraged the use of a treatment plan in primary care for older adults 
with multiple chronic conditions, where consideration had been given to prognosis, 
treatment/condition interactions, benefits and harms of treatments, and subsequent reassessment 
[46].  Although the AGS and NICE guidelines do not specifically consider situations in which patients 
are unable to participate in care discussions due to acute severe illness, delirium, dementia, or 
severe frailty, a proactive approach to treatment plan development prior to crises or loss of capacity 
should be considered good practice. 
An additional challenge in the management of multimorbidity is the relative paucity of evidence to 
date on the effectiveness of interventions to improve outcomes in this construct, in contrast to the 
more robust evidence available for a Comprehensive Geriatric Assessment in the management of 
frailty [47].  A recent Cochrane review of interventions in multimorbidity in primary care and 
community settings highlighted the limited number of randomised controlled trials (RCTs) and their 
mixed results [48].  The interventions were largely focussed on care delivery, which translated into 
probable improvements in mental health outcomes and patient-reported outcomes, but not into 
clinical outcomes or health service use.  Further intervention studies are required in this area.   
A more nuanced approach to multimorbidity management has been highlighted in a recent 
interesting discussion paper [31].  The authors emphasise the importance of bio-psycho-social 
factors in the context of physiological dysregulation of the neuroendrocrine, immune and 
mitochondrial systems.  They postulate that future care of the multimorbid patient might include 
small molecule therapeutics to target the complex molecular and cellular dysfunction, together with 
environmental factors such as health behaviour, emotional and social support and stress 
management [31]. 
Conclusions and future directions 
Multimorbidity is a highly prevalent, highly relevant concept for specialists working with older 
people.  Although research has been traditionally centred in primary care, multimorbidity is 
synonymous with the challenges faced by geriatricians, where the complexity of disease processes 
and polypharmacy is particularly onerous for individuals, their families and for the health service.  
While previous research has investigated the cross-sectional overlap between comorbidity and 
frailty, there is a paucity of research on the temporal relationships between single LTCs, 
multimorbidity, frailty and disability.  Furthermore, there is a paucity of research involving people 
with neurodegenerative disease who have multiple LTCs, with the exception of limited work in 
dementia. 
The development of a cohesive research strategy on how to meet the needs of older people with 
multimorbidity is a key priority.   In the UK, the National Institute for Health Research has prioritised 
this research area, indicating ongoing commitment to strengthening the evidence base for older 
people with complex health needs (http://www.nihr.ac.uk/funding-and-support/themed-calls/). 
NICE has recommended that key topics for research in this field are the organisation of care, holistic 
assessment in the community, stopping preventive medicines and predicting life expectancy [10].  
These key topic areas require further refinement to align with the priorities of older people, the 
public and health care practitioners; views which are currently actively being sought and prioritised 
in a James Lind Alliance priority setting partnership 
(https://research.ncl.ac.uk/jlaprioritysetting/ageingmultimorbidity/). 
Future research should focus on these areas, with definitive RCTs of suitably targeted interventions, 
together with the exploration of putative common underlying physiological process to identify novel 
therapeutic targets.  As geriatricians, we are ideally placed to advance this field of research and 
ensure that the new horizon in multimorbidity is informed by a robust evidence base that is aligned 
with the complex health needs of older people. 
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